Form 10-Q OptiNose, Inc. For: Sep 30

Go back to Form 10-Q OptiNose, Inc. For: Sep 30

Optinose (OPTN) PT Lowered to $5 at BMO Capital

November 11, 2022 8:53 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $5.00 (from $6.00) while maintaining an Outperform rating.

The analyst commented, "3Q Xhance rev. missed by $3mm, but OPTN managed expenses offsetting that for in-line EPS. Xhance is facing some NT... More